List of Rhofade drug patents

Rhofade is owned by Epi Hlth.

Rhofade contains Oxymetazoline Hydrochloride.

Rhofade has a total of 8 drug patents out of which 0 drug patents have expired.

Rhofade was authorised for market use on 18 January, 2017.

Rhofade is available in cream;topical dosage forms.

Rhofade can be used as once daily topical treatment of persistent facial erythema associated with rosacea in female adults, once daily topical treatment of persistent facial erythema associated with rosacea in adults, once daily topical treatment of persistent facial erythema associated with rosacea in adults with 1% oxymetazoline hydrochloride cream, topical treatment of persistent facial erythema associated with rosacea in adults with 1% oxymetazoline hydrochloride cream, once daily topical treatment of persistent facial erythema associated with rosacea in adults with 1% oxymetazoline hydrochloride cream, where the patient experiences no rebound or worsening of facial erythema post-treatment.

The generics of Rhofade are possible to be released after 11 June, 2035.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8815929 EPI HLTH Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
Jan, 2024

(11 months from now)

US8420688 EPI HLTH Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
Aug, 2024

(1 year, 5 months from now)

US7812049 EPI HLTH Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
May, 2028

(5 years from now)

US8883838 EPI HLTH Pharmaceutical cream compositions and methods of use
Dec, 2031

(8 years from now)

US9974773 EPI HLTH Stabilized oxymetazoline formulations and their uses
Jun, 2035

(12 years from now)

US10751325 EPI HLTH Stabilized oxymetazoline formulations and their uses
Jun, 2035

(12 years from now)

US10335391 EPI HLTH Stabilized oxymetazoline formulations and their uses
Jun, 2035

(12 years from now)

US11517560 EPI HLTH Stabilized oxymetazoline formulations and their uses
Jun, 2035

(12 years from now)

Drugs and Companies using OXYMETAZOLINE HYDROCHLORIDE ingredient

Market Authorisation Date: 18 January, 2017

Treatment: Topical treatment of persistent facial erythema associated with rosacea in adults with 1% oxymetazoline hydrochloride cream; Once daily topical treatment of persistent facial erythema associated with rosacea in adults with 1% oxymetazoline hydrochloride cream; Once daily topical treatment of persistent facial erythema associated with rosacea in adults; Once daily topical treatment of persistent facial erythema associated with rosacea in adults with 1% oxymetazoline hydrochloride cream, where the patient experiences no rebound or worsening of facial erythema post-treatment; Once daily topical treatment of persistent facial erythema associated with rosacea in female adults

Dosage: CREAM;TOPICAL

How can I launch a generic of RHOFADE before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic